Emerging New Biomarkers of Preeclampsia

Advances in Chronic Kidney Disease

Volumn 20, Issue 3, 2013, Pages 271-279

  Polsani, Srujana ^a   Phipps, Elizabeth ^b   Jim, Belinda ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW YORK INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Biomarker; Podocyte; Preeclampsia; Pregnancy; Proteomics

Indexed keywords

ALBUMIN; ANGIOTENSIN II; BIOLOGICAL MARKER; ENDOGLIN; ENDOTHELIN 1; GLOMERULAR EPITHELIAL PROTEIN 1; NEPHRIN; NITRIC OXIDE; PLACENTA PROTEIN; PLACENTAL GROWTH FACTOR; PLACENTAL PROTEIN 13; PLASMA PROTEIN; PLASMA PROTEIN 13; PODOCALYXIN; PROSTACYCLIN; PROTEIN TYROSINE PHOSPHATASE; SERINE PROTEINASE INHIBITOR; SERPINA1; THROMBOXANE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; FLOW MEASUREMENT; HUMAN; METABOLOMICS; PODOCYTE; PREECLAMPSIA; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RISK FACTOR; UTERINE ARTERY DOPPLER VELOCIMETRY;

ANTIGENS, CD; BIOLOGICAL MARKERS; FEMALE; GALECTINS; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; RECEPTORS, CELL SURFACE; UTERINE ARTERY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84876866465     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2013.01.001     Document Type: Review

References (85)

1. Khan K.S., Wojdyla D., Say L., Gulmezoglu A.M., Van Look P.F. WHO analysis of causes of maternal death: a systematic review. Lancet 2006, 367(9516):1066-1074.
2. Xiong X., Demianczuk N.N., Buekens P., Saunders L.D. Association of preeclampsia with high birth weight for age. Am J Obstet Gynecol 2000, 183(1):148-155.
3. Friedman S.A., Schiff E., Kao L., Sibai B.M. Neonatal outcome after preterm delivery for preeclampsia. Am J Obstet Gynecol 1995, 172(6):1785-1788. discussion 1788-1792.
4. Vestergaard M., Basso O., Henriksen T.B., Ostergaard J., Secher N.J., Olsen J. Pre-eclampsia and febrile convulsions. Arch Dis Childhood 2003, 88(8):726-727.
5. Bellamy L., Casas J.P., Hingorani A.D., Williams D.J. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007, 335(7627):974.
6. Vikse B.E., Irgens L.M., Leivestad T., Skjaerven R., Iversen B.M. Preeclampsia and the risk of end-stage renal disease. N Engl J Med 2008, 359(8):800-809.
7. Matthys L.A., Coppage K.H., Lambers D.S., Barton J.R., Sibai B.M. Delayed postpartum preeclampsia: an experience of 151 cases. Am J Obstet Gynecol 2004, 190(5):1464-1466.
8. Khalil A, Rezende J, Akolekar R, Syngelaki A, Nicolaides KH. Maternal racial origin and adverse pregnancy outcomes: a cohort study. Ultrasound Obstet Gynecol. doi:10.1002/uog.12313.2012.
9. Esplin M.S., Fausett M.B., Fraser A., et al. Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med 2001, 344(12):867-872.
10. Robillard P.Y., Hulsey T.C., Perianin J., Janky E., Miri E.H., Papiernik E. Association of pregnancy-induced hypertension with duration of sexual cohabitation before conception. Lancet 1994, 344(8928):973-975.
11. Skjaerven R., Wilcox A.J., Lie R.T. The interval between pregnancies and the risk of preeclampsia. N Engl J Med 2002, 346(1):33-38.
12. England L., Zhang J. Smoking and risk of preeclampsia: a systematic review. Front Biosci 2007, 12:2471-2483.
13. Mehendale R., Hibbard J., Fazleabas A., Leach R. Placental angiogenesis markers sFlt-1 and PlGF: response to cigarette smoke. Am J Obstet Gynecol 2007, 197(4):e361-e365.
14. Schutte J.M., Schuitemaker N.W., van Roosmalen J., Steegers E.A., Dutch Maternal Mortality Committee Substandard care in maternal mortality due to hypertensive disease in pregnancy in the Netherlands. BJOG 2008, 115(6):732-736.
15. Reslan O.M., Khalil R.A. Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia. Cardiovasc Hematol Agents Med Chem 2010, 8(4):204-226.
16. Levine R.J., Lam C., Qian C., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006, 355(10):992-1005.
17. Levine R.J., Maynard S.E., Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004, 350(7):672-683.
18. Rana S., Karumanchi S.A., Levine R.J., et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007, 50(1):137-142.
19. Moore Simas T.A., Crawford S.L., Solitro M.J., Frost S.C., Meyer B.A., Maynard S.E. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 2007, 197(3):e241-e248.
20. Su Y.N., Lee C.N., Cheng W.F., Shau W.Y., Chow S.N., Hsieh F.J. Decreased maternal serum placenta growth factor in early second trimester and preeclampsia. Obstet Gynecol 2001, 97(6):898-904.
21. Tjoa M.L., van Vugt J.M., Mulders M.A., Schutgens R.B., Oudejans C.B., van Wijk I.J. Plasma placenta growth factor levels in midtrimester pregnancies. Obstet Gynecol 2001, 98(4):600-607.
22. Polliotti B.M., Fry A.G., Saller D.N., Mooney R.A., Cox C., Miller R.K. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003, 101(6):1266-1274.
23. Hertig A., Berkane N., Lefevre G., et al. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem 2004, 50(9):1702-1703.
24. Krauss T., Pauer H.U., Augustin H.G. Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy 2004, 23(1):101-111.
25. Bersinger N.A., Odegard R.A. Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Acta Obstet Gynecol Scand 2004, 83(1):37-45.
26. Park C.W., Park J.S., Shim S.S., Jun J.K., Yoon B.H., Romero R. An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia. Am J Obstet Gynecol 2005, 193(3 Pt 2):984-989.
27. Vatten L.J., Eskild A., Nilsen T.I., Jeansson S., Jenum P.A., Staff A.C. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 2007, 196(3):e231-e236.
28. Smith G.C., Crossley J.A., Aitken D.A., et al. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol 2007, 109(6):1316-1324.
29. Vaisbuch E., Whitty J.E., Hassan S.S., et al. Circulating angiogenic and antiangiogenic factors in women with eclampsia. Am J Obstet Gynecol 2011, 204(2):e151-e159.
30. Noori M., Donald A.E., Angelakopoulou A., Hingorani A.D., Williams D.J. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010, 122(5):478-487.
31. Levine R.J., Thadhani R., Qian C., et al. Urinary placental growth factor and risk of preeclampsia. JAMA 2005, 293(1):77-85.
32. Thadhani R., Mutter W.P., Wolf M., et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004, 89(2):770-775.
33. Levine R.J., Qian C., Maynard S.E., Yu K.F., Epstein F.H., Karumanchi S.A. Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. Am J Obstet Gynecol 2006, 194(4):1034-1041.
34. De Vivo A., Baviera G., Giordano D., Todarello G., Corrado F., D'Anna R. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 2008, 87(8):837-842.
35. McElrath T.F., Lim K.H., Pare E., et al. Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. Am J Obstet Gynecol 2012, 207:407.e1-407.e7.
36. Sunderji S., Gaziano E., Wothe D., et al. Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstet Gynecol 2010, 202(1):e41-e47.
37. Kusanovic J.P., Romero R., Chaiworapongsa T., et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009, 22(11):1021-1038.
38. Aggarwal P.K., Jain V., Sakhuja V., Karumanchi S.A., Jha V. Low urinary placental growth factor is a marker of pre-eclampsia. Kidney Int 2006, 69(3):621-624.
39. Savvidou M.D., Akolekar R., Zaragoza E., Poon L.C., Nicolaides K.H. First trimester urinary placental growth factor and development of pre-eclampsia. BJOG 2009, 116(5):643-647.
40. Buhimschi C.S., Baumbusch M.A., Dulay A.T., et al. The role of urinary soluble endoglin in the diagnosis of pre-eclampsia: comparison with soluble fms-like tyrosine kinase 1 to placental growth factor ratio. BJOG 2010, 117(3):321-330.
41. Perni U., Sison C., Sharma V., et al. Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension 2012, 59(3):740-746.
42. Rolfo A., Attini R., Nuzzo A.M., et al. Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney Int 2013, 83(1):177-181.
43. Masuyama H., Nobumoto E., Okimoto N., Inoue S., Segawa T., Hiramatsu Y. Superimposed preeclampsia in women with chronic kidney disease. Gynecol Obstet Invest 2012, 74(4):274-281.
44. Chafetz I., Kuhnreich I., Sammar M., et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 2007, 197(1):e31-e37.
45. Huppertz B., Sammar M., Chefetz I., Neumaier-Wagner P., Bartz C., Meiri H. Longitudinal determination of serum placental protein 13 during development of preeclampsia. Fetal Diagn Ther 2008, 24(3):230-236.
46. Romero R., Kusanovic J.P., Than N.G., et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol 2008, 199(2):122.e1-122.e11.
47. Stamatopoulou A., Cowans N.J., Matwejew E., von Kaisenberg C., Spencer K. Placental protein-13 and pregnancy-associated plasma protein-A as first trimester screening markers for hypertensive disorders and small for gestational age outcomes. Hypertens Pregnancy 2011, 30(4):384-395.
48. Akolekar R., Syngelaki A., Beta J., Kocylowski R., Nicolaides K.H. Maternal serum placental protein 13 at 11-13 weeks of gestation in preeclampsia. Prenatal Diagn 2009, 29(12):1103-1108.
49. Odibo A.O., Zhong Y., Goetzinger K.R., et al. First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia. Placenta 2011, 32(8):598-602.
50. Steel S.A., Pearce J.M., Chamberlain G. Doppler ultrasound of the uteroplacental circulation as a screening test for severe pre-eclampsia with intra-uterine growth retardation. Eur J Obstet Gynecol Reprod Biol 1988, 28(4):279-287.
51. Aardema M.W., De Wolf B.T., Saro M.C., Oosterhof H., Fidler V., Aarnoudse J.G. Quantification of the diastolic notch in Doppler ultrasound screening of uterine arteries. Ultrasound Obstet Gynecol 2000, 16(7):630-634.
52. Papageorghiou A.T., Leslie K. Uterine artery Doppler in the prediction of adverse pregnancy outcome. Curr Opin Obstet Gynecol 2007, 19(2):103-109.
53. Espinoza J., Romero R., Nien J.K., et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 2007, 196(4):326.e1-326.e13.
54. Stepan H., Unversucht A., Wessel N., Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007, 49(4):818-824.
55. Cnossen J.S., Morris R.K., ter Riet G., et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ 2008, 178(6):701-711.
56. Barton J.R., Sibai B.M. Prediction and prevention of recurrent preeclampsia. Obstet Gynecol 2008, 112(2 Pt 1):359-372.
57. Poon L.C., Kametas N.A., Maiz N., Akolekar R., Nicolaides K.H. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009, 53(5):812-818.
58. Eremina V., Sood M., Haigh J., et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003, 111(5):707-716.
59. Garovic V.D., Wagner S.J., Petrovic L.M., et al. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transpl 2007, 22(4):1136-1143.
60. Garovic V.D., Wagner S.J., Turner S.T., et al. Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol 2007, 196(10):320.e1-320.e7.
61. Zhao S., Gu X., Groome L.J., Wang Y. Decreased nephrin and GLEPP-1, but increased VEGF, Flt-1, and nitrotyrosine, expressions in kidney tissue sections from women with preeclampsia. Reprod Sci 2009, 16(10):970-979.
62. Collino F., Bussolati B., Gerbaudo E., et al. Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells. Am J Physiol Renal Physiol 2008, 294(5):F1185-F1194.
63. Aita K., Etoh M., Hamada H., et al. Acute and transient podocyte loss and proteinuria in preeclampsia. Nephron Clin Pract 2009, 112(2):c65-c70.
64. Jim B., Jean-Louis P., Qipo A., et al. Podocyturia as a diagnostic marker for preeclampsia amongst high-risk pregnant patients. J Pregnancy 2012, 2012:984630.
65. Wang Y., Zhao S., Loyd S., Groome L.J. Increased urinary excretion of nephrin, podocalyxin, and betaig-h3 in women with preeclampsia. Am J Physiol Ren Physiol 2012, 302(9):F1084-F1089.
66. Kelder T.P., Penning M.E., Uh H.W., et al. Quantitative polymerase chain reaction-based analysis of podocyturia is a feasible diagnostic tool in preeclampsia. Hypertension 2012, 60:1538-1544.
67. Greene C.S., Troyanskaya O.G. Integrative systems biology for data-driven knowledge discovery. Semin Nephrol 2010, 30(5):443-454.
68. Barratt J., Topham P. Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ 2007, 177(4):361-368.
69. Buhimschi I.A., Zhao G., Funai E.F., et al. Proteomic profiling of urine identifies specific fragments of SERPINA1 and albumin as biomarkers of preeclampsia. Am J Obstet Gynecol 2008, 199(5):551.e1-551.e16.
70. Bergman D., Kadner S.S., Cruz M.R., et al. Synthesis of alpha 1-antichymotrypsin and alpha 1-antitrypsin by human trophoblast. Pediatr Res 1993, 34(3):312-317.
71. Linja-Aho A., Mazur W., Toljamo T., et al. Distribution and levels of alpha-1-antitrypsin in the lung and plasma in smokers and chronic obstructive pulmonary disease. APMIS 2013, 121:11-21.
72. Engstrom G., Janzon L., Berglund G., et al. Blood pressure increase and incidence of hypertension in relation to inflammation-sensitive plasma proteins. Arterioscler Thromb Vasc Biol 2002, 22(12):2054-2058.
73. Chen G., Zhang Y., Jin X., et al. Urinary proteomics analysis for renal injury in hypertensive disorders of pregnancy with iTRAQ labeling and LC-MS/MS. Proteomics Clin Appl 2011, 5(5-6):300-310.
74. Carty D.M., Siwy J., Brennand J.E., et al. Urinary proteomics for prediction of preeclampsia. Hypertension 2011, 57(3):561-569.
75. Kottgen A., Glazer N.L., Dehghan A., et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet 2009, 41(6):712-717.
76. Wishart D.S., Knox C., Guo A.C., et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res 2009, 37:D603-D610.
77. Odibo A.O., Goetzinger K.R., Odibo L., et al. First-trimester prediction of preeclampsia using metabolomic biomarkers: a discovery phase study. Prenatal Diagn 2011, 31(10):990-994.
78. Bahado-Singh R.O., Akolekar R., Mandal R., et al. Metabolomics and first-trimester prediction of early-onset preeclampsia. J Matern Fetal Neonatal Med 2012, 25(10):1840-1847.
79. Thadhani R., Kisner T., Hagmann H., et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011, 124(8):940-950.
80. Duckitt K., Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005, 330(7491):565.
81. Davies A.M., Czaczkes J.W., Sadovsky E., Prywes R., Weiskopf P., Sterk V.V. Toxemia of pregnancy in Jerusalem. I. Epidemiological studies of a total community. Isr J Med Sci 1970, 6(2):253-266.
82. Kleinrouweler C.E., Wiegerinck M.M., Ris-Stalpers C., et al. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG 2012, 119(7):778-787.
83. Lim J.H., Kim S.Y., Park S.Y., et al. Soluble endoglin and transforming growth factor-beta1 in women who subsequently developed preeclampsia. Prenatal Diagn 2009, 29(5):471-476.
84. Stepan H., Geipel A., Schwarz F., Kramer T., Wessel N., Faber R. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol 2008, 198(2):175.e1-175.e6.
85. Tidwell S.C., Ho H.N., Chiu W.H., Torry R.J., Torry D.S. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001, 184(6):1267-1272.